The Fundación EMpresas IQS has added a new member in Noucor, a pharmaceutical and chemical company with a presence in more than 100 countries. The company formally joined the foundation during an institutional event held on 17 January at the IQS campus.
The Fundación Empresas IQS has added a new member in Noucor, a pharmaceutical and chemical company with a presence in more than 100 countries. The company formally joined through an institutional event held on 17 January at the IQS campus. David Perdigó, Noucor’s CEO, Josep Pérez de Tudela, Director of Human Resources, and Maribel Sanjurjo, Head of Communications, attended the event on behalf of Noucor. Representing IQS at the event were Dr Salvador Borrós, Director of IQS, and Rosa Curt, Director of the IQS Business Foundation.
Noucor is a recently created pharmaceutical and chemical company (the result of the spinoff from the pharmaceutical company Uriach), with a B2B business model, backed by an extensive history of more than two centuries in the sector and with a presence in more than 100 markets worldwide. The company is a venture of the investment fund MCH and a private group of investors.
Noucor has a 100% industrial focus. Headquartered near Barcelona, the company has three manufacturing plants: a fine chemistry plant (Urquima) located in Sant Fost de Campsentelles dedicated to the production of active pharmaceutical ingredients, a pharmaceutical plant, and a plant exclusively focused on food supplements, the latter two both located in Palau-Solità i Plegamans. The three production centres employ more than 450 people.
Noucor’s three main business areas are innovative products (New Chemical Entities), generic products, and Contract Manufacturing (CMO). The company focuses on global sales of active pharmaceutical ingredients (API) and pharmaceutical products, with a wide portfolio of various specialities such as the central nervous system, the respiratory system, dermatology, cardiovascular health, and urology.
Noucor’s most notable milestones include the launch of its star product, the antihistamine Rupatadine, in key markets like Japan and Canada, the company’s consolidation in the European market, and its recent entry into the Chinese market.